Compositions and methods for adoptive cell therapy for cancer
US-12241097-B2 · Mar 4, 2025 · US
Compositions and methods for adoptive cell therapy
US12496310B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12496310-B2 |
| Application number | US-201816627270-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 2, 2018 |
| Priority date | Jun 30, 2017 |
| Publication date | Dec 16, 2025 |
| Grant date | Dec 16, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.
First claim
Opening claim text (preview).
What is claimed is: 1 . An engineered immune cell comprising: (a) a prodrug converting enzyme and/or a nucleic acid encoding the prodrug converting enzyme, wherein the prodrug converting enzyme is Pseudomonas sp. Carboxypeptidase G2 (CPG2) or Enterobacter cloacae β-lactamase; and (b) a chimeric antigen receptor (CAR) comprising a first transmembrane domain, wherein the CAR is expressed on the surface of the engineered immune cell and binds to a target antigen, and/or a nucleic acid encoding the CAR, wherein the CAR targets the engineered immune cell to a site of pathogenic infection and wherein the target antigen is an antigen from a pathogen, wherein the prodrug converting enzyme is: (i) secreted from the engineered immune cell, or (ii) expressed on the surface of the immune cell and is (A) fused to a second transmembrane domain; or (B) attached to the surface of the cell by a GPI anchor, wherein the first transmembrane domain of the CAR is separate from the second transmembrane domain of the prodrug converting enzyme, wherein the antigen from the pathogen is a bacterial antigen, a parasitic antigen, a HSV-1 protein antigen, a HSV-2 protein antigen, or an HIV-1 protein antigen. 2 . The engineered immune cell of claim 1 , wherein the nucleic acid encoding the prodrug converting enzyme is operably linked to a constitutive promoter or a conditional promoter and comprises a leader sequence for secretion of the prodrug converting enzyme. 3 . The engineered immune cell of claim 1 , wherein the CAR comprises (i) an extracellular antigen binding domain, (ii) the first transmembrane domain, and (iii) an intracellular domain. 4 . The engineered immune cell of claim 3 , wherein the extracellular antigen binding domain binds to the antigen from the pathogen, wherein the antigen from the pathogen is: (i) a bacterial antigen selected from the group consisting of a Pasteurella species, Staphylococci species, Streptococcus species, Escherichia coli, Pseudomonas species , and Salmonella species bacteria, or wherein the bacterial antigen is at least one of a peptidoglycan antigen, a capsule antigen or a cell wall antigen; or (ii) a HSV-1 or HSV-2 protein antigen selected from the group consisting of gB, gD, gH, VP16, and VP22, or (iii) an HIV-1 protein antigen selected from the group consisting of gp120, gp41, gp160, gag, and pol. 5 . The engineered immune cell of claim 3 , wherein the extracellular antigen binding domain comprises a single chain variable fragment (scFv); or wherein the first transmembrane domain comprises a CD8 transmembrane domain, a CD28 transmembrane domain or an ICOS transmembrane domain; or wherein the intracellular domain comprises one or more costimulatory domains selected from a CD28 costimulatory domain, a CD32-chain, a 4-1BBL costimulatory domain, an OX40 costimulatory domain, an ICOS costimulatory domain, and a DAP10 costimulatory domain; or wherein a signal peptide is covalently joined to the N-terminus of the extracellular antigen binding domain. 6 . The engineered immune cell of claim 1 , wherein the engineered immune cell is a lymphocyte, a T cell, a B cell, or a natural killer cell, and wherein the T cell is a CD4+ T cell or a CD8+ T cell. 7 . The engineered immune cell of claim 1 , wherein the second transmembrane domain fused to the prodrug converting enzyme comprises a CD8 transmembrane domain.
Assignees
Inventors
Classifications
Wilms tumor 1 [WT1] · CPC title
CD19 or B4 · CPC title
PRAME · CPC title
Viral antigens · CPC title
Bacterial antigens · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12496310B2 cover?
- Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.
- Who is the assignee on this patent?
- Memorial Sloan Kettering Cancer Center
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7076. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).